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Abstract
Objective/Background: According to the U.S. Census Bureau, 18% of the total population in the United States identiﬁed
themselves as Hispanic in 2016 making it the largest minority group. This study aimed to evaluate the effect of Hispanic
ethnicity on the overall survival of patients with non-small cell lung cancer (NSCLC) using a large national cancer database.
Methods: We used the National Cancer Database to identify patients diagnosed with NSCLC between 2010 and 2015.
The two comparative groups for this study were non-Hispanic Whites (NHWs) and Hispanics. The primary outcome was
overall survival.
Results: Of the 555,475 patients included in the study, 96.9% and 3.1% were NHWs and Hispanics with a median follow
up of 12.6 months (interquartile range 4.1e30.6) and 12.1 months (interquartile range 3.8e29.5), respectively. Hispanics
were more likely to be uninsured, and live in areas with lower median household income or education level. In the age-,
sex-, and comorbidities-adjusted Cox model, the overall survival was signiﬁcantly better in Hispanics compared with
NHWs (hazard ratio [HR] 0.92, 95% conﬁdence interval 0.90e0.93, p < .001). In a demographic, socioeconomic, clinical,
and facility characteristics adjusted Cox model, Hispanics had further improvement in survival (HR 0.79, 95% conﬁdence
interval 0.78e0.81, p < .001). The survival advantage was seen in all cancer stages: Stage IdHR 0.76 (0.71e0.80), Stage
IIdHR 0.85 (0.79e0.92), Stage IIIdHR 0.81 (0.77e0.85), and Stage IVdHR 0.79 (0.77e0.81).
Conclusion: Hispanic ethnicity was associated with better survival in NSCLC. This survival advantage is likely the
result of complex interactions amongst several physical, social, cultural, genomic, and environmental factors.
Keywords: Carcinoma, Non-small-cell lung, Ethnic groups, Hispanic Americans/statistics & numerical data, Registries,
Survival rate

1. Introduction

A

ccording to the U.S. Census Bureau, 18% of
the total population in the United States
identiﬁed themselves as Hispanic in 2016 making it
the largest minority group [1]. Hispanics are known
to have lower average socioeconomic status and
limited health care access compared with non-Hispanic Whites (NHWs) [2e4]. Even with the aforementioned inequalities, several studies have
concluded that Hispanics have health outcomes
comparable to or even better than NHWs for certain
medical conditions [2,5]. This observation has been

termed as the “Hispanic Paradox” [6]. Several social,
genetic, and lifestyle factors have been proposed to
explain the Hispanic Paradox [5,7,8].
The incidence and mortality of lung cancer in
Hispanics are approximately 50% lower than in
NHWs [9]. Nonetheless, lung cancer remains the
leading cause of cancer-related deaths in both Hispanics and NHWs [9,10]. Studies on the relationship
between Hispanic ethnicity and non-small cell lung
(NSCLC) survival have had inconsistent conclusions
[11e17]. This study aimed to evaluate the effect of
Hispanic ethnicity on the overall survival of patients
with NSCLC using a large national cancer database.
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This database collects extensive data variables for
analyses that allowed us to explore the impact of
various socioeconomic, demographic, and clinical
characteristics on the overall survival [18].

2. Methods
2.1. Data source
We used the National Cancer Database (NCDB) to
identify patients diagnosed with NSCLC between
2010 and 2015. The NCDB is a nationwide oncology
database that prospectively collects from more than
1500 Commission on Cancer-accredited programs
and includes ~70% of all new cancer diagnoses in
the United States [18]. The database provides a wide
array of de-identiﬁed information about patient
demographics, tumor-speciﬁc details, facility, the
ﬁrst course of cancer treatment, and overall survival.
The study was approved by the Institutional Review
Board, University of Louisville, Kentucky.
2.2. Cohort selection and outcomes
The two comparative groups for this study were
NHWs and Hispanics. The cohort selection criteria
are shown in Fig. 1. Hispanic ethnicity was

identiﬁed using the NCDB coding variable “SPANISH_HISPANIC_ORIGIN”. This variable codes
Hispanic ethnicity by origin (Mexican, Cuban,
Puerto Rican, etc.). Of note, the majority of the patients (61%) were coded as Hispanic “not otherwise
speciﬁed”. The country of birth data is not collected
by the NCDB. A sensitivity analysis was done to
evaluate the impact of the missing Hispanic
ethnicity status (Appendix Table A1).
The primary outcome was overall survival. The
NCDB does not collect information on diseasespeciﬁc survival. The impact of available socioeconomic (insurance type, income, and level of education)
demographic,
clinical,
and
facility
characteristics on overall survival was also analyzed.
Education and income variables in the NCDB are
deﬁned as the number of adults in the patient’s zip
code who did not graduate from high school and
median household income for each patient’s area of
residence, and are estimated by matching the zip
code of the patient recorded at the time of diagnosis
against ﬁles derived from the American Community
Survey data and adjusted for inﬂation, respectively.
Both education and household income are categorized as quartiles based on equally proportioned
ranges among all U.S. zip codes [18].

Fig. 1. Flow diagram of study population. NCDB ¼ National Cancer Database; NSCLC ¼ non-small cell lung cancer.
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2.3. Statistical analysis
Baseline characteristics were compared between
NHWs and Hispanics using the Fisher exact test for
the categorical variables and the Wilcoxon ranksum test for the continuous variables. The
KaplaneMeier method was used to estimate unadjusted survival times which were compared with the
log-rank test. The multivariable Cox regression
model was built by including all clinically relevant
covariates that were signiﬁcantly associated with the
outcome of univariable analysis with a cutoff p value
of 0.2 (Appendix Table A2). All clinically relevant
interactions between the covariates were also
included in the model. The proportional hazards
assumption was tested using statistical tests and
graphical diagnostics based on the scaled Schoenfeld residuals. The model was stratiﬁed on the
nonproportional covariates. Finally, we evaluated
the ﬁt of the ﬁnal model by using the CoxeSnell
residuals. To elucidate the effect of demographic,
socioeconomic, clinical, and facility characteristics
on overall survival in NSCLC, four separate multivariate survival models were built. Model 1 was
adjusted for age, sex, and comorbidities. Model 2
included covariates in Model 1 plus socioeconomic
factors (insurance, education, and income level).
Model 3 included covariates in Model 2 plus facility
type, location, and distance. Finally, Model 4
included covariates in Model 3 plus stage, histology,
and treatment modalities. The covariates were
introduced into the model using a staged approach
to provide insight into which covariates had a relatively greater inﬂuence on the effect estimate. A
two-sided p value < 0.05 was considered statistically
signiﬁcant. All the analyses were performed by
STATA statistical software, version 16 (Stata Corporation, College Station, TX, USA).

3. Results
A total of 555,475 patients met the inclusion
criteria for this study (Fig. 1). The NHWs and Hispanics comprised 96.9% and 3.1% of the study
cohort with a median follow up of 12.6 months
(interquartile range [IQR] 4.1e30.6) and 12.1 months
(IQR 3.8e29.5), respectively. The demographics and
clinical characteristics of the patients are shown in
Table 1. Hispanics were younger and had a lower
proportion of females compared with the NHWs
cohort. Hispanics were more likely to be uninsured
(7.1% vs. 2.6%, p < .001) and lived in areas with
lower median household income (27.7% vs. 17.3%

Table 1. Demographics and clinical characteristics of the study
population.

Sample size (n ¼ 555,475)
Age, y (%)
 <60
 60e75
 >75
Female (%)
Insurance (%)
 None
 Private
 Governmenta
Median household
income, $ (%)
 <40,227
 40,227e50,353
 50,354e63,332
 >63,332
Educationb (%)
 17.6
 10.9e17.5
 6.3e10.8
 <6.3
Charlson-Deyo
comorbidity score (%)
 <1
 1
Stage (%)
 I
 II
 III
 IV
Histology (%)
 Adenocarcinoma
 Squamous
 Other
Treatment modality (%)
 Chemotherapy
 Surgery
 Radiation
 No treatment
Facility typec (%)
 CCP
 CCCP
 ARP
 ICP
Facility locationc (%)
 Northwest
 West
 Midwest
 South

Non-Hispanic
Whites

Hispanics

538,305

17,170

18.9
51.8
29.3
48.5

22.6
50
27.4
44.6

2.6
25.8
71.6

7.1
24.3
68.6

p value

<0.001

<0.001
<0.001

<0.001
17.3
24.4
25
33.3

27.7
24.4
24.1
23.8

17.7
28.1
30.6
23.6

53
21.6
16.1
9.3

<0.001

0.001
55.8
44.2

58.7
41.3

29.2
10.3
20.1
40.4

24.2
9.3
19.4
47.1

55.8
29.6
14.6

61
23.8
15.2

45.1
30.9
42.9
11.8

46
28.6
36.3
16.5

10.3
45.3
30.4
14

8
37.7
38.6
15.7

21.6
12.8
28
37.6

19.4
30
8.5
42.1

<0.001

<0.001

0.017
<0.001
<0.001
<0.001
<0.001

<0.001

Note. ARP ¼ academic/research practice; CCCP ¼ Comprehensive Community Cancer Program; CCP ¼ community cancer
practice; ICP ¼ integrated cancer practice; y ¼ year.
a
Medicare, Medicaid and other government insurance.
b
Education: This provides a measure of the percentage of
adults in the patient’s zip code who did not graduate from highschool and is categorized as equally proportioned quartiles
among all US zip codes.
c
Suppressed for age < 40 y.
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with income <$40,227; p < .001), and lower education level (53% vs. 17.7% where  17.6% adults did
not graduate from high school; p < .001). Hispanics
had a higher likelihood of advanced disease stage at
diagnosis, adenocarcinoma histology, and of
receiving no cancer-directed treatment compared
with NHWs. Initial treatment at an academic institution was received by 38.6% with median distance
traveled for treatment being 6.7 miles (IQR 3.3e13.4)
compared with that by 30.4% and 10.5 miles (IQR
4.5e24.7) in Hispanic and NHW groups, respectively ( p < .001 for all comparisons).
In the age-, sex-, and comorbidities-adjusted
survival model (Model 1), Hispanics had a statistically signiﬁcant improvement in survival compared
with NHWs (hazard ratio [HR] 0.92, 95% conﬁdence
interval [CI] 0.90e0.93, p < .001). In Model 4
(adjusted for all covariates) the Hispanics had
further improvement in survival (HR 0.79, 95% CI
0.78e0.81, p < .001). The higher proportion of
advanced cancer stage and no cancer-directed
treatment in Hispanics were the most signiﬁcant
covariates that, when adjusted, explained the survival difference between Model 1 and Model 4. The
HRs of all the models are shown in Table 2. The
median overall survival was 17.9 months (95% CI
17.1e18.5) in Hispanics and 15.9 months (95% CI
15.8e16.0) in NHWs, p < .001 (Fig. 2). The median
overall survival and 5-year overall survival rate
stratiﬁed by stage are shown in Table 3. In Model 4
subgroup analysis, Hispanics had better survival in
all cancer stages: stage IdHR 0.76 (95% CI
0.71e0.80), stage IIdHR 0.85 (95% CI 0.79e0.92),
stage IIIdHR 0.81 (95% CI 0.77e0.85), and stage
IVdHR 0.79 (95% CI 0.77e0.81).
In subgroup analysis, Hispanic ethnicity was
associated with better survival in all the age groups
(27% in < 60 years, 19% in 60e75 years, and 19% in
> 75 years), and both sexes (malesd20% and
femalesd21%). The improvement in survival in
Hispanics was by 36% in the uninsured patients,

Table 2. Cox proportional hazard models for mortality in non-hispanic
whites and hispanics with non-small cell lung cancer.

Model
Model
Model
Model
a

1a
2b
3c
4d

Non-Hispanic
White

Hispanics
HR [95%CI]

p value

Reference
Reference
Reference
Reference

0.92
0.88
0.91
0.79

<0.001
<0.001
<0.001
<0.001

(0.90e0.93)
(0.87e0.90)
(0.89e0.92)
(0.78e0.81)

Model 1: adjusted for age, sex, and comorbidities.
Model 2: Model 1 plus insurance status, education, and income level.
c
Model 3: Model 2 plus facility type, location, and distance.
d
Model 4: Model 3 plus stage, histology, and treatment.
b

22% in the lowest income quartile, and 21% in
lowest education quartile compared with NHWs in
the same subgroups. Interestingly, the survival was
comparatively even better in the lowest socioeconomic group (uninsured, lowest income, and education quartile), HR 0.55 (95% CI 0.47e0.64, p < .001)
than the highest group (private insurance, highest
income, and education quartile), HR 0.77 (95% CI
0.68e0.88, p < .001) (Figs. 3 and 4). An improvement
in survival was also seen in all histologic subtypes
(adenocarcinomad23%, squamousd14%). Detailed
subgroup analyses are available in Appendix
Table A3.

4. Discussion
In our study, we used a large database to determine the effect of Hispanic ethnicity on the NSCLC
overall survival in the United States. Previous
studies have inconsistently reported similar or better NSCLC survival outcomes in Hispanics
compared with other racial/ethnic groups
[11,12,14,16]. We report an 8% better survival in
Hispanics with NSCLC compared with NHWs in
age, sex, and comorbidities adjusted model. When
we adjusted for all the potential confounders (Model
4), the survival was further improved by 22% in
Hispanics.
The Hispanic population is especially vulnerable
to cancer care disparities due to disproportionately
lower socioeconomic status compared with NHW
population [2e4]. Consequently, Hispanic patients
have a higher likelihood of having de novo advanced
stage and receive no treatment [9]. There are several
socioeconomic determinants of health like income,
education, culture/linguistic barriers, insurance, and
occupation that lead to underutilization of health
care by the Hispanic community [19]. In our study,
maybe the reason adjusting for available socioeconomic factors (Model 2) did not fully account for the
higher proportion of advanced disease and recipient
of no treatment (Model 4) in Hispanics is because
we were able to include only three available socioeconomic factorsdinsurance, zip code level income,
and education in the model. Although, some studies
have reported a higher risk of advanced-stage cancer diagnosis in Hispanics even when socioeconomic status and health care access are similar
[20,21].
Several factors have been suggested to explain the
“Hispanic paradox” including the low prevalence of
smoking, community support, genetics, dietary
habits, and selective immigration patterns [5,7,8,14].
Due to the limitations of the database, we were
unable to determine the effects of these factors. A
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Fig. 2. Kaplan-Meier estimates of overall survival in Hispanics versus Non-Hispanic Whites.

study by Patel et al. [22] in women reported that
decreased mortality risk in Hispanics was attenuated when adjusted for several sociodemographic
factors including, but not limited to education, diet,
and physical activity. Lower smoking prevalence
has been reported in the U.S. Hispanic population
than in NHWs (15.4% vs. 22.2% in 2009, respectively) [23]. This overall lower tobacco smoking
prevalence and the trend towards less daily cigarette consumption in the Hispanic population may
partly explain the lower risk of mortality in patients
with NSCLC [24] and also the explanation for the
higher proportion of adenocarcinoma NSCLC subtype [25]. Interestingly, a multiethnic cohort study
showed that smoking-associated lung cancer risk
was higher in NHWs compared with Hispanics,
even after matching for cigarette consumption
implicating genetic predisposition [26,27].
Studies have reported higher epidermal growth
factor receptor (EGFR) (26e48%) and lower KRAS

(14e16%) mutation frequencies in Hispanics
[28e31]. The identiﬁcation of driver mutations like
EGFR has led to the development of targeted therapy in NSCLC that has signiﬁcantly improved the
survival of patients with metastatic disease [32].
Also, a higher response rate has been reported in
MexicaneHispanic patients with EGFR-mutated
NSCLC treated with erlotinib, particularly those
who had wood-smoke exposure [33]. Although
currently there is no approved therapy directed
against KRAS, mutated status has been associated
with a worse prognosis [34]. In contrast, the frequencies of EGFR and KRAS mutation are approximately 20% and 27% in the NHWs, respectively
[31,35,36].
Moreover, in our study Hispanics had better
overall survival outcomes in early-stage lung cancers treated with curative intent. Studies with
competing risk analysis have suggested that this
may be due to an increased risk of mortality in

Table 3. Median Survival Time (mOS) and 5-y Overall Survival (OS) Rate of Non-Small Cell Lung Cancer in Non-Hispanic Whites and Hispanics
Stratiﬁed by Stage.
Non-Hispanic Whites

Hispanics

Stage

mOS, mo (95% CI)

5-y OS (%)

mOS, mo (95% CI)

5 y OS (%)

p value

I
II
III
IV
Overall

58.5 (57.9e59.0)
32.2 (31.6e32.8)
15.8 (15.6e16.0)
5.4 (5.3e5.5)
15.9 (15.8e16.0)

49.1
34.1
16.6
4.1
22.8

Not reached
39.3 (35.5e46.3)
19.5 (18.0e20.8)
7.1 (6.7e7.4)
17.9 (17.1e18.5)

58.6
40.9
23.1
8
26.7

<0.001
<0.001
<0.001
<0.001
<0.001

Note. CI ¼ conﬁdence interval; mo, month; y ¼ year.
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Fig. 3. Kaplan-Meier estimates of overall survival in Hispanics versus Non-Hispanic Whites in the lowest socioeconomic group (uninsured, lowest
income, and education quartile). CI ¼ conﬁdence interval; mo ¼ month; OS ¼ overall survival.

NHWs from causes like a cardiovascular and pulmonary disease rather than lung cancer itself [37,38].
Other studies have pointed toward the genomic
proﬁle of Hispanics as a possible contributing factor
[39,40].

The concept of healthy migration and “Salmon
bias” postulates that there is a selective pressure on
the healthier population to migrate to the United
States and the sick patients tend to migrate back to
their native countries, respectively [41]. The return

Fig. 4. Kaplan-Meier estimates of overall survival in Hispanics versus Non-Hispanic Whites in the highest socioeconomic group (private insurance,
highest income, and education quartile).
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of patients to their native country after diagnosis
may lead to incomplete death ascertainment. One
study using the California Cancer Registry has
shown better NSCLC survival outcomes in the
foreign compared with the U.S.-born Hispanic
population [14]. Acculturation with the adaptation of
high-risk habits like increase in smoking, obesity,
alcohol consumption, dietary changes, and a
decrease in physical activity in the U.S.-born Hispanics likely plays a role in this survival difference
and further highlights the impact of these factors on
health outcomes [42e44]. Although, this migration
pattern may contribute to, but does not completely
explain the better health outcomes of Hispanics in
the United States [41].
Regarding dietary habits, of particular interest is
the fact that there could be an up to ﬁve times
higher yearly consumption of legumes among Hispanics. Legumes may decrease systemic inﬂammation that has been linked to susceptibility to chronic
obstructive pulmonary disease and lung cancer [45].
Limitations of this study include the unavailability
of variables like the country of birth, smoking status,
driver mutations, detailed comorbidities, and performance status that may affect the NSCLC survival
outcomes. Details about systemic therapy like the
use of target and immuno therapies were also unavailable. Patient-level income and education along
with other social determinants of health are not
available. Also, the NCDB does not report recurrence-free or cancer-speciﬁc survival. The NCDB is
not a population-based database and includes only
patients treated at Commission on Cancer designated programs that tend to have more cancer care
services and are in urban locations [46]. Of note, it is
important to point out that Hispanics are a very
heterogeneous population due to several different
ethnic origins (e.g., Mexicans, Puerto Ricans, and
Cubans, etc.) that were not accounted for in this
study. There are signiﬁcant health, social, and cultural differences amongst these nativities that may
impact health outcomes [47].
The Hispanic population is one of the most
rapidly growing in the United States and is projected to be 29%dmore than one-quarter of the U.S.
population by 2060 [1]. Although the Hispanic
ethnicity appears to be associated with better
NSCLC survival in the United States, there are
signiﬁcant health inequalities. The Hispanic survival advantage is likely the result of complex interactions amongst several physical, social, genomic,
and environmental factors. Future studies must
attempt to elucidate these factors to not only
improve cancer survival in Hispanics, but also to
integrate modiﬁable prognostic factors in the care of
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the general population. With precision medicine
reshaping the ﬁeld of oncology, focusing on the
genomic proﬁle of NSCLC in the minority populations that are underrepresented in clinical trials
is essential to advance care in these populations.
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